(Q33391725)

English

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Pier Luigi Zinzani

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Liliana Devizzi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Stefano Luminari

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

10

object named as

F Cavalli

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

A Conconi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

G Martinelli

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

A Lopez-Guillermo

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

A J M Ferreri

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

L Rigacci

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

International Extranodal Lymphoma Study Group (IELSG)

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

689-695

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

State-of-the-art therapeutics: marginal-zone lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Radiation therapy for localized low-grade non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

The proteasome: a suitable antineoplastic target

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Delving deeper into MALT lymphoma biology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Review of survival analyses published in cancer journals

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

A phase II study of bortezomib in patients with MALT lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

The 26 S proteasome: from basic mechanisms to drug targeting

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ416

21 January 2018

Identifiers

10.1093/ANNONC/MDQ416

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20810546%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33391725&oldid=1558050648"